These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 26043810

  • 21. Velaglucerase alfa: a new option for Gaucher disease treatment.
    Zimran A.
    Drugs Today (Barc); 2011 Jul; 47(7):515-29. PubMed ID: 22013559
    [Abstract] [Full Text] [Related]

  • 22. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
    Zimran A, Wajnrajch M, Hernandez B, Pastores GM.
    Orphanet J Rare Dis; 2018 Feb 23; 13(1):36. PubMed ID: 29471850
    [Abstract] [Full Text] [Related]

  • 23. Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan.
    Sagara R, Ishigaki M, Otsuka M, Murayama K, Ida H, Fernandez J.
    Orphanet J Rare Dis; 2021 Dec 04; 16(1):502. PubMed ID: 34863216
    [Abstract] [Full Text] [Related]

  • 24. Management of Gaucher disease: enzyme replacement therapy.
    Zimran A, Elstein D.
    Pediatr Endocrinol Rev; 2014 Sep 04; 12 Suppl 1():82-7. PubMed ID: 25345089
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
    Laudemann K, Moos L, Mengel E, Lollert A, Hoffmann C, Brixius-Huth M, Wagner D, Düber C, Staatz G.
    Blood Cells Mol Dis; 2016 Mar 04; 57():35-41. PubMed ID: 26852653
    [Abstract] [Full Text] [Related]

  • 26. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM.
    Curr Opin Investig Drugs; 2010 Apr 04; 11(4):472-8. PubMed ID: 20336596
    [Abstract] [Full Text] [Related]

  • 27. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
    Elstein D, Haims AH, Zahrieh D, Cohn GM, Zimran A.
    Blood Cells Mol Dis; 2014 Apr 04; 53(1-2):56-60. PubMed ID: 24581483
    [Abstract] [Full Text] [Related]

  • 28. Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey.
    Deegan P, Fernandez-Sasso D, Giraldo P, Lau H, Panahloo Z, Zimran A.
    Blood Cells Mol Dis; 2018 Feb 04; 68():218-225. PubMed ID: 27829541
    [Abstract] [Full Text] [Related]

  • 29. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction.
    Elstein D, Foldes AJ, Zahrieh D, Cohn GM, Djordjevic M, Brutaru C, Zimran A.
    Blood Cells Mol Dis; 2011 Jun 15; 47(1):56-61. PubMed ID: 21536468
    [Abstract] [Full Text] [Related]

  • 30. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
    Zimran A, Elstein D, Gonzalez DE, Lukina EA, Qin Y, Dinh Q, Turkia HB.
    Blood Cells Mol Dis; 2018 Feb 15; 68():153-159. PubMed ID: 27839979
    [Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of velaglucerase alfa replacement therapy for patients with type 1 Gaucher disease.
    Elstein D, Zimran A.
    Expert Rev Endocrinol Metab; 2013 Jul 15; 8(4):333-339. PubMed ID: 30736148
    [Abstract] [Full Text] [Related]

  • 32. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.
    Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, Wang N, Bhirangi K, Cohn GM, Elstein D.
    Blood; 2010 Jun 10; 115(23):4651-6. PubMed ID: 20299511
    [Abstract] [Full Text] [Related]

  • 33. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
    Cravo R, Rotman V, Oliveira PMN, Defendi HGT, Conceição DA, Xavier JR, Chertkoff R, Noronha TG, Maia MLS.
    Blood Cells Mol Dis; 2018 Feb 10; 68():160-162. PubMed ID: 28131618
    [Abstract] [Full Text] [Related]

  • 34. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 10; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 35. Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.
    Pleat R, Cox TM, Burrow TA, Giraldo P, Goker-Alpan O, Rosenbloom BE, Croal LR, Underhill LH, Gaemers SJ, Peterschmitt MJ.
    Mol Genet Metab Rep; 2016 Dec 10; 9():25-28. PubMed ID: 27722092
    [Abstract] [Full Text] [Related]

  • 36. Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.
    van Dussen L, Cox TM, Hendriks EJ, Morris E, Akkerman EM, Maas M, Groener JE, Aerts JM, Deegan PB, Hollak CE.
    Haematologica; 2012 Dec 10; 97(12):1850-4. PubMed ID: 22773601
    [Abstract] [Full Text] [Related]

  • 37. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease.
    Elstein D, Hughes D, Goker-Alpan O, Stivel M, Baris HN, Cohen IJ, Granovsky-Grisaru S, Samueloff A, Mehta A, Zimran A.
    J Obstet Gynaecol Res; 2014 Apr 10; 40(4):968-75. PubMed ID: 24612151
    [Abstract] [Full Text] [Related]

  • 38. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease.
    Elstein D, Burrow TA, Charrow J, Giraldo P, Mehta A, Pastores GM, Lee HM, Mellgard B, Zimran A.
    Mol Genet Metab; 2017 Apr 10; 120(1-2):111-115. PubMed ID: 27614581
    [Abstract] [Full Text] [Related]

  • 39. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
    Elstein D, Mellgard B, Dinh Q, Lan L, Qiu Y, Cozma C, Eichler S, Böttcher T, Zimran A.
    Mol Genet Metab; 2017 Sep 10; 122(1-2):113-120. PubMed ID: 28851512
    [Abstract] [Full Text] [Related]

  • 40. Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States.
    Nalysnyk L, Sugarman R, Cele C, Uyei J, Ward A.
    J Manag Care Spec Pharm; 2018 Oct 10; 24(10):1002-1008. PubMed ID: 30247105
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.